DUBLIN, June 2, 2023 /PRNewswire/ — The “Global Musculoskeletal Partnering 2016-2023: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.
This report provides the full collection of musculoskeletal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.
- Trends in musculoskeletal partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Musculoskeletal partnering agreement structure
- Musculoskeletal partnering contract documents
- Top musculoskeletal deals by value
- Most active musculoskeletal dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering musculoskeletal deals.
The report presents financial deal terms values for musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
The report is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide.
Global Musculoskeletal Partnering 2016 to 2023 includes:
- Trends in musculoskeletal dealmaking in the biopharma industry since 2016
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of musculoskeletal deal contract documents
- Comprehensive access to over 600 musculoskeletal deal records
- The leading musculoskeletal deals by value since 2016
- Most active musculoskeletal dealmakers since 2016
The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthritis, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget’s disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications.
In Global Musculoskeletal Partnering 2016 to 2023, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Musculoskeletal Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 – Introduction
Chapter 2 – Trends in musculoskeletal dealmaking
2.1. Introduction
2.2. Musculoskeletal partnering over the years
2.3. Musculoskeletal partnering by deal type
2.4. Musculoskeletal partnering by industry sector
2.5. Musculoskeletal partnering by stage of development
2.6. Musculoskeletal partnering by technology type
2.7. Musculoskeletal partnering by therapeutic indication
Chapter 3 -Financial deal terms for musculoskeletal partnering
3.1. Introduction
3.2. Disclosed financials terms for musculoskeletal partnering
3.3. Musculoskeletal partnering headline values
3.4. Musculoskeletal deal upfront payments
3.5. Musculoskeletal deal milestone payments
3.6. Musculoskeletal royalty rates
Chapter 4 – Leading musculoskeletal deals and dealmakers
4.1. Introduction
4.2. Most active in musculoskeletal partnering
4.3. List of most active dealmakers in musculoskeletal
4.4. Top musculoskeletal deals by value
Chapter 5 – Musculoskeletal contract document directory
5.1. Introduction
5.2. Musculoskeletal partnering deals where contract document available
Chapter 6 – Musculoskeletal dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by musculoskeletal therapeutic target
Companies Mentioned
- 3D-Side
- 3SBio
- A2A Pharmaceuticals
- Aavis Pharmaceuticals
- Abarca
- Abbvie
- AbCellera
- AC Bioscience
- Accenture
- Actigraph
- Activbody
- Active Implants
- Adaptive Health
- Additive Orthopaedics
- Advanced Human Imaging
- AdventHealth
- Affinia Therapeutics
- AGC Asahi Glass
- AgNovos Healthcare
- AgomAb Therapeutics
- Akashi Therapeutics
- AKL Research and Development
- AlfaMed
- Aligos Therapeutics
- AliMed
- Alkem Laboratories
- Allergan
- AlloSource
- Almirall
- Alpine Immune Sciences
- Altamira Bio
- Altasciences
- Alvogen
- Alvotech
- Ambry Genetics
- Amedica
- Amend Surgical
- American Association of Neuromuscular & Electrodiagnostic Medicine
- Amgen
- Amneal Pharmaceuticals
- AMRA
- AMRA Medical
- Anagenesis Biotechnologies
- Analysis Group
- AnaMar
- Angelini Pharma
- Angers University
- Anika Therapeutics
- ANI Pharmaceuticals
- Antares Pharma
- Antibe Therapeutics
- Apexigen
- Apple
- Apsen Farmacutica
- Aptahem
- Aptorum Group
- Aralez Pharmaceuticals
- Aratana Therapeutics
- Aravive Biologics
- argenx
- ARK Crystal
- Arrowhead Pharmaceuticals
- Arthrex
- Arthrosi Therapeutics
- Artialis
- Asahi Kasei
- Ascendis Pharma
- AskAt
- Asklepios Biopharmaceutical
- Assertio Therapeutics
- Astellas Pharma
- AstraZeneca
- Athrotech
- Atnahs Pharma
- Audentes Therapeutics
- Aurinia Pharmaceuticals
- Australian Research Council
- Autotelic BIO
- Avalere Health
- Avanos Medical
- Aveta Biomics
- AveXis
- Avidity Biosciences
- Avion Pharmaceuticals
- AWB Schraubtechnik und Industriebedarf
- Axovant Gene Therapies
- Azellon Cell Therapeutics
- Aziyo Biologics
- Back-A-Line
- Bacterin International
- Baebies
- Bamboo Therapeutics
- Bauerfeind
- Baxalta
- Bayer
- Baylor College of Medicine
- Bazis NN
- BC Platforms
- Beijing Tide Pharmaceutical
- Benitec Biopharma
- Berg
- BGI
- BillionToOne
- Bio-Thera Solutions
- BioAge Labs
- BioCanRx
- Biocomposites
- Biogen
- BioGen Medical
- Biohaven Pharmaceuticals
- BioInvent
- BioMarin Pharmaceutical
- BioMed X Innovation Center
- BionX Medical Technologies
- BioPharma Forest
- Bioqube Ventures
- Bioservo Technologies
- Biosolution
- Biosplice
- Bioventus
- BioVinc
- Bison & Rose
- Blue Belt Technologies
- Blueprint Medicines
- Bodycad
- Boehringer Ingelheim
- Bone Biologics
- Bone Therapeutics
- Brickell Biotech
- Brigham and Women’s Hospital
- Bristol-Myers Squibb
- BRM Extremities
- BSN Medical
- Burke Therapeutics
- c-LEcta
- California Institute for Biomedical Research
- California Institute for Regenerative Medicine
- Calimmune
- Calliditas Therapeutics
- Camargo Pharmaceutical Services
- Camber Spine Technologies
- Can-Fite BioPharma
- CANbridge Pharmaceuticals
- Cantargia
- Capricor Therapeutics
- Capsigen
- CareFirst BlueCross BlueShield
- Carlsmed
- Carna BioSciences
- CartiHeal
- Cartiva
- CAS
- Casper Pharma
- Catabasis Pharmaceuticals
- Catalyst Pharmaceuticals
- cbdMD
- Cedars-Sinai Medical Center
- Celgene
- Celltech
- Cellthera Pharma
- Cell Therapy Catapult
- Celltrion
- Cellular Biomedicine
- Cel Sci
- Centinel Spine
- Centogene
- Cerhum
For more information about this report visit https://www.researchandmarkets.com/r/f6nnrt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
